Welcome to LookChem.com Sign In|Join Free
  • or
J&J Ex-61, also known as JNJ-38877605, is a potent inhibitor of c-Met catalytic activity with high selectivity over other tyrosine and serine-threonine kinases. It has demonstrated the ability to block constitutive or HGF-stimulated phosphorylation of c-Met in vitro.

943540-75-8

Post Buying Request

943540-75-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

943540-75-8 Usage

Uses

Used in Oncology:
J&J Ex-61 is used as an anticancer agent for its ability to reduce radiation-induced invasion, apoptosis, and proliferation of cancer cells in vitro. Its high selectivity for c-Met makes it a promising candidate for targeted cancer therapies.
Used in Pharmaceutical Industry:
J&J Ex-61 is used as a research compound for studying the role of c-Met in various cellular processes and its potential as a therapeutic target for cancer treatment. Its high selectivity and in vitro efficacy make it a valuable tool for drug discovery and development.

Biological Activity

jnj-38877605 is a small-molecule atp-competitive inhibitor of the catalytic activity of c-met.extensive evidence that c-met signaling is involved in the progression and spread of several cancers and an enhanced understanding of its role in disease have generated considerable interest in c-met and hgf asmajor targets in anti-cancer drug development.

in vitro

jnj-38877605 showed ~600-fold selectivity for c-met compared with a panel of ~250 diverse tyrosine and serine-threonine kinases and was found to potently inhibit hgf-stimulated and constitutively activated c-met phosphorylation in vitro [1].

in vivo

jnj-38877605 showed excellent oral bioavailability approaching 100% in all examined species. in addition, jnj-38877605 in a single dose was observed toinhibit met phosphorylation in tumor xenografts for up to16 h. inhibition of met phosphorylation was associated withdose-dependent tumor growth inhibition using a range of oral dosing regimens [2].

references

[1] pererat, l avrijssent, janssens b, et al. jnj-38877605: a selective met kinase inhibitor inducingregression of met-driven tumor models. presented at the 99th aacr annual meeting; 2008 apr 12 -16;

Check Digit Verification of cas no

The CAS Registry Mumber 943540-75-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,3,5,4 and 0 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 943540-75:
(8*9)+(7*4)+(6*3)+(5*5)+(4*4)+(3*0)+(2*7)+(1*5)=178
178 % 10 = 8
So 943540-75-8 is a valid CAS Registry Number.
InChI:InChI=1/C19H13F2N7/c1-27-11-13(10-23-27)16-6-7-17-24-25-18(28(17)26-16)19(20,21)14-4-5-15-12(9-14)3-2-8-22-15/h2-11H,1H3

943540-75-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name JNJ-38877605

1.2 Other means of identification

Product number -
Other names JNJ38877605

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:943540-75-8 SDS

943540-75-8Downstream Products

943540-75-8Relevant academic research and scientific papers

POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE

-

, (2009/01/23)

The invention relates to novel polymorphic and hydrate forms and salts of 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline, to methods for their preparation, to pharmaceutical compositions comprising at least one of said polymorphic or hydrate forms or salts, and to the therapeutic and/or prophylactic use of such compositions. The invention also provides new manners for preparing said compound.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 943540-75-8